» Articles » PMID: 30607110

Outcomes by Treatment Modality in Elderly Patients with Localized Gastric and Esophageal Cancer

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2019 Jan 5
PMID 30607110
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We aimed to assess current treatment patterns and outcomes in elderly patients with localized gastric and esophageal (ge) cancers.

Methods: This retrospective analysis considered patients 75 years of age or older with ge cancers treated during 2012-2014. Patient demographics and tumour characteristics were collected. Overall survival (os) and disease-free survival were assessed by univariable and multivariable Cox proportional hazards regression, adjusting for demographics. Logistic regression analyses were used to examine factors affecting treatment choices.

Results: The 110 patients in the study cohort had a median age of 81 years (range: 75-99 years). Primary disease sites were esophageal (55%) and gastric (45%). Treatment received included radiation therapy alone (29%), surgery alone (26%), surgery plus perioperative therapy (14%), chemoradiation alone (10%), and supportive care alone (14%). In multivariable analyses, surgery (hazard ratio: 0.48; 95% confidence interval: 0.26 to 0.90; = 0.02) was the only independent predictor for improved os. Patients with a good Eastern Cooperative Oncology Group performance status ( = 0.008), gastric disease site ( = 0.02), and adenocarcinoma histology ( = 0.01) were more likely to undergo surgery.

Conclusions: At our institution, few patients 75 years of age and older received multimodality therapy for localized ge cancers. Outcomes were better for patients who underwent surgery than for those who did not. To ensure optimal treatment selection, comprehensive geriatric assessment should be considered for patients 75 years of age and older with localized ge cancers.

Citing Articles

Outcomes from a single institution cohort of 248 patients with stage I-III esophageal cancer treated with radiotherapy: Comparison of younger and older populations.

Lavergne C, Youssef A, Niglas M, Humphreys D, Youssef Y Tech Innov Patient Support Radiat Oncol. 2024; 31:100260.

PMID: 39070540 PMC: 11278076. DOI: 10.1016/j.tipsro.2024.100260.


Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy.

Wang X, Allen M, Espin-Garcia O, Suzuiki C, Bach Y, Panov E Oncologist. 2024; 29(11):e1501-e1510.

PMID: 39046894 PMC: 11546644. DOI: 10.1093/oncolo/oyae190.


The TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain.

Vera R, Castro N, Labiano I, Lecumberri A, Huerta A, Arasanz H BMC Cancer. 2024; 24(1):668.

PMID: 38824512 PMC: 11143674. DOI: 10.1186/s12885-024-12454-9.


Increasing disparities in the proportions of active treatment and 5-year overall survival over time by age groups among older patients with gastric cancer in Korea.

Zhang H, Choi D, Kim H, Kang H, Jhang H, Jeong W Front Public Health. 2023; 10:1030565.

PMID: 36699910 PMC: 9869046. DOI: 10.3389/fpubh.2022.1030565.


HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies.

Ieni A, Cardia R, Pizzimenti C, Zeppa P, Tuccari G J Pers Med. 2020; 10(1).

PMID: 32098203 PMC: 7151629. DOI: 10.3390/jpm10010010.

References
1.
Smith B, Smith G, Hurria A, Hortobagyi G, Buchholz T . Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17):2758-65. DOI: 10.1200/JCO.2008.20.8983. View

2.
Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P . Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003; 21(19):3580-7. DOI: 10.1200/JCO.2003.02.046. View

3.
Kalsi T, Babic-Illman G, Ross P, Maisey N, Hughes S, Fields P . The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer. 2015; 112(9):1435-44. PMC: 4453673. DOI: 10.1038/bjc.2015.120. View

4.
Parker S, Tong T, Bolden S, Wingo P . Cancer statistics, 1997. CA Cancer J Clin. 1997; 47(1):5-27. DOI: 10.3322/canjclin.47.1.5. View

5.
Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View